# EDGAR Filing Document

**Accession Number:** 0001680367
**File Stem:** 0000899243-23-010102
**Filing Date:** 2023-3
**Character Count:** 10000
**Document Hash:** 38f6714e8b4a30d4015158261204a553
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-010102.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0000899243-23-010102

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230323

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Stout Stephen
- **CENTRAL INDEX KEY:** 0001970664

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39593
- **FILM NUMBER:** 23788458

**MAIL ADDRESS:**
- **STREET 1:** C/O SHATTUCK LABS, INC.
- **STREET 2:** 500 W. 5TH STREET, SUITE 1200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shattuck Labs, Inc.
- **CENTRAL INDEX KEY:** 0001680367
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 812575858
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 500 W. 5TH STREET
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
- **BUSINESS PHONE:** 512-900-4690

**MAIL ADDRESS:**
- **STREET 1:** 500 W. 5TH STREET
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701

## Ex-24

```
<PRE>
                               POWER OF ATTORNEY

     Know all by these presents that the undersigned hereby constitutes and
appoints each of Andrew R. Neill and Taylor Schreiber, and any of their
substitutes, signing singly, as the undersigned's true and lawful attorney-in-
fact to:

1.   prepare, execute in the undersigned's name and on the undersigned's behalf,
     and submit to the U.S. Securities and Exchange Commission (the "SEC") a
     Form ID, including amendments thereto, and any other document necessary or
     appropriate to obtain codes, passwords, and passphrases enabling the
     undersigned to make electronic filings with the SEC of reports require by
     the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

2.   execute for and on behalf of the undersigned, in the undersigned's capacity
     as a director and/or officer of Shattuck Labs, Inc. (the "Company"), Forms
     3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act
     of 1934 and the rules thereunder;

3.   do and perform any and all acts for and on behalf of the undersigned which
     may be necessary or desirable to complete and execute any such Form 3, 4,
     or 5, complete and execute any amendment or amendments thereto, and timely
     file such form with the SEC and any securities exchange or similar
     authority; and

4.   take any other action of any type whatsoever in connection with the
     foregoing which, in the opinion of such attorney-in-fact, may be of benefit
     to, in the best interest of, or legally required by, the undersigned, it
     being understood that the documents executed by such attorney-in-fact on
     behalf of the undersigned pursuant to this Power of Attorney shall be in
     such form and shall contain such terms and conditions as such attorney-in-
     fact may approve in such attorney-in-fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned also ratifies hereby any action previously taken by
each attorney-in-fact that would have been authorized by this power of attorney
if it has been in effect at the time such action was taken.  The undersigned
acknowledges that each attorney-in-fact, in serving in such capacity at the
request of the undersigned, is not assuming, nor is the Company assuming, any of
the undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

     This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) undersigned is no longer required to file Forms 3, 4,
and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-
in-fact individually, until such attorney-in-fact is no longer employed by the
Company or its subsidiaries.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of March 22, 2023.

                                    /s/ Stephen Stout
                                    -----------------------------
                                    Stephen Stout

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Stout Stephen<br><sub>(Last) (First) (Middle)</sub><br>C/O SHATTUCK LABS, INC.<br>500 W. 5TH STREET, SUITE 1200<br><sub>(Street)</sub><br>AUSTIN, TX 78701<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Shattuck Labs, Inc. [ STTK ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-23 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_See Remarks_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 14975<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2031-04-09 | Common Stock | 14300 | $28.23 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2032-01-10 | Common Stock | 34875 | $7.43 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2032-09-08 | Common Stock | 13950 | $3.51 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2033-01-25 | Common Stock | 23850 | $3.57 | D |  |

---

### Footnotes:

(1) Consists of 14,975 restricted stock units ("RSUs"), 1,744 of which have vested. 5,231 RSUs will vest in three approximately equal annual installments beginning on January 10, 2024 and 8,000 RSUs will vest in four equal annual installments beginning on January 25, 2024, in each case subject to the Reporting Person's continued service to the Issuer.

(2) This option represents a right to purchase a total of 14,300 shares of the Issuer's common stock, 6,852 of which have vested, with the remaining vesting in approximately equal monthly installments through April 10, 2025, subject to the Reporting Person's continued service to the Issuer.

(3) This option represents a right to purchase a total of 34,875 shares of the Issuer's common stock, 10,172 of which have vested, with the remaining vesting in approximately equal monthly installments through January 10, 2026, subject to the Reporting Person's continued service to the Issuer.

(4) This option represents a right to purchase a total of 13,950 shares of the Issuer's common stock, one-third of which will vest on September 8, 2023 and two-thirds of which will vest on September 8, 2024, subject to the Reporting Person's continued service to the Issuer.

(5) This option represents a right to purchase a total of 23,850 shares of the Issuer's common stock, one-quarter of which will vest on January 25, 2024, with the remaining three-quarters vesting in approximately equal monthly installments through December 10, 2025, subject to the Reporting Person's continued service to the Issuer.

**Remarks:**
Deputy General Counsel and Vice President of Intellectual Property

Exhibit 24 - Power of Attorney

**Signature:** /s/ Stephen Stout  
**Date:** 2023-03-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**